http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
-
Completion of share buy-back program
-
Transactions in connection with share buy-back program
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Transactions in connection with share buy-back program
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Transactions in connection with share buy-back program
-
Genmab A/S (GMAB) Improves FY22 Financial Guidance
-
Genmab Improves Its 2022 Financial Guidance
-
Transactions in connection with share buy-back program
-
Genmab A/S (GMAB) and BioNTech (BNTX) Expand Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
-
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
-
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
-
Major Shareholder Announcement
-
Transactions in connection with share buy-back program
-
Transactions in connection with share buy-back program
-
Major Shareholder Announcement
-
Genmab A/S (GMAB) Reports Q2 Net Sales of DARZALEX of $1.97B
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
-
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-
-
Genmab (GMAB) Announces That AbbVie (ABBV) Will Submit MAA to EMA for Epcoritamab for the Treatment of R/R DLBCL
-
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-
-
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-
-
Transactions in connection with share buy-back program
-
Major Shareholder Announcement
-
Major Shareholder Announcement
-
Genmab A/S (GMAB) to Submit BLA to FDA for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
-
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
-
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Major Shareholder Announcement
-
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology A
-
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology A
-
Genmab A/S (GMAB) Commences New Arbitration Under License Agreement With Janssen
-
Genmab Commences New Arbitration Under License Agreement With Janssen
-
Grant of Restricted Stock Units and Warrants to Employees in Genmab
-
Genmab (GMAB) and Seagen (SGEN) Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
-
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
-
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
-
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
-
Major Shareholder Announcement
-
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress
-
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
-
Genmab A/S (GMAB) Reports Q1 Net Sales of DARZALEX of $1.86B
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
-
AbbVie (ABBV) and Genmab (GMAB) Report Topline Results for Epcoritamab from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma
-
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
